Join Drs Tania Jain and Aaron Gerds as they discuss the latest developments in clinical trials and investigational therapeutics for MPNs.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999594. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Primary Myelofibrosis https://emedicine.medscape.com/article/197954-overview

Myeloproliferative Neoplasms https://www.ncbi.nlm.nih.gov/books/NBK531464/

Bromodomain and Extraterminal (BET) Proteins: Biological Functions, Diseases, and Targeted Therapy https://pubmed.ncbi.nlm.nih.gov/37926722/

Long-Term Survival in Patients Treated With Ruxolitinib for Myelofibrosis: COMFORT-I and -II Pooled Analyses https://pubmed.ncbi.nlm.nih.gov/28962635/

Rampal RK, Grosicki S, Chraniuk S, et al. Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naïve patients with myelofibrosis: results of the MANIFEST-2 randomized, double-blind, phase 3 study. Program and abstracts of the 65th American Society of Hematology Annual Meeting and Exposition; December 10, 2023; San Diego, California. Abstract 628. https://ash.confex.com/ash/2023/webprogram/Paper179141.html

Pemmaraju N, Mead AJ, Somervaille T CP, et al.Transform-1: A randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis. Program and abstracts of the 65th American Society of Hematology Annual Meeting and Exposition; December 10, 2023; San Diego, California. Abstract 620. https://ash.confex.com/ash/2023/webprogram/Paper173509.html

Defining Disease Modification in Myelofibrosis in the Era of Targeted Therapy https://pubmed.ncbi.nlm.nih.gov/35499819/

A Prognostic Model to Predict Survival After 6 Months of Ruxolitinib in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35130339/

Imetelstat in Patients With Lower-Risk Myelodysplastic Syndromes Who Have Relapsed or Are Refractory to Erythropoiesis-Stimulating Agents (IMerge): A Multinational, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/38048786/

Join Drs Tania Jain and Pankit Vachhani as they discuss the nuance involved in the risk stratification of myelofibrosis and the latest research in prefibrotic myelofibrosis.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999593. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Primary Myelofibrosis: Risk Stratification by IPSS Identifies Patients With Poor Clinical Outcome https://pubmed.ncbi.nlm.nih.gov/23644853/

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status https://pubmed.ncbi.nlm.nih.gov/21149668/

Predicting Survival After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model https://pubmed.ncbi.nlm.nih.gov/32717433/

New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment https://pubmed.ncbi.nlm.nih.gov/18988864/

GIPSS: Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/29654267/

Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project https://ashpublications.org/blood/article/124/21/405/115226/Mutation-Enhanced-International-Prognostic-Scoring

MIPSS70+ v2.0 Predicts Long-Term Survival in Myelofibrosis After Allogeneic HCT With the Flu/Mel Conditioning Regimen https://pubmed.ncbi.nlm.nih.gov/30622146/

MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/29708808/

U2AF1 Mutation Types in Primary Myelofibrosis: Phenotypic and Prognostic Distinctions https://pubmed.ncbi.nlm.nih.gov/29535431/

A Clinical-Molecular Prognostic Model to Predict Survival in Patients With Post Polycythemia Vera and Post Essential Thrombocythemia Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/28561069/

MYSEC Prognostic Model Risk Calculator (MYSEC-PM) http://www.mysec-pm.eu/

A Prognostic Model to Predict Survival After 6 Months of Ruxolitinib in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35130339/

Survival Following Allogeneic Transplant in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/32384540/

A Simple Prognostic System in Patients With Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation: A CIBMTR/EBMT Analysis https://pubmed.ncbi.nlm.nih.gov/37134306/

SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/38341324/

IPSET Thrombosis Risk for ET https://thehematologist.org/ipset-thrombosis/